Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - olmesartan medoxomil ; hydrochlorothiazide ep - film coated tablet - 20/25 milligram - olmesartan medoxomil and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - olmesartan medoxomil ; hydrochlorothiazide ep - film coated tablet - 40/25 milligram - olmesartan medoxomil and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - olmesartan medoxomil ; hydrochlorothiazide ep - film coated tablet - 40/12.5 milligram - olmesartan medoxomil and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 20 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 20 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 40 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - olmesartan medoxomil; hydrochlorothiazide - film-coated tablet - 40 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

United States - English - NLM (National Library of Medicine)

apotex corp. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10) - amlodipine 5 mg - amlodipine and olmesartan medoxomil tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine and olmesartan medoxomil tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - hydrochlorothiazide ep; olmesartan medoxomil - film-coated tablet - 20/12.5 - angiotensin ii antagonists and diuretics; olmesartan medoxomil and diuretics

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - olmesartan medoxomil (unii: 6m97xtv3hd) (olmesartan - unii:8w1iqp3u10), amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - olmesartan medoxomil 20 mg - olmesartan medoxomil, amlodipine, hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (cv) events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such